No outbreak of vancomycin and linezolid resistance in staphylococcal pneumonia over a 10-year period

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Yayan, Josef ^a   Ghebremedhin, Beniam ^b   Rasche, Kurt ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Center for Clinical and Translational Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; GERMANY; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RETROSPECTIVE STUDY; STAPHYLOCOCCAL PNEUMONIA; UNIVERSITY HOSPITAL; DRUG EFFECTS; EPIDEMIC; KAPLAN MEIER METHOD; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PNEUMONIA, STAPHYLOCOCCAL; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; VANCOMYCIN;

EID: 84946949457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138895     Document Type: Article

References (87)

1. Ryu S, Song PI, Seo CH, Cheong H, Park Y. Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides. Int J Mol Sci. 2014; 15: 8753-8772. doi: 10.3390/ijms15058753 PMID: 24840573
2. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011; 9: 244-253. doi: 10.1038/ nrmicro2537 PMID: 21407241
3. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007; 51: 3568-3573. PMID: 17682100
4. Steinbach WJ, Shetty AK. Use of the diagnostic bacteriology laboratory: a practical review for the clinician. Postgrad Med J. 2001; 77: 148-156. PMID: 11222821
5. Boks NP, Kaper HJ, Norde W, van der Mei HC, Busscher HJ. Mobile and immobile adhesion of staphylococcal strains to hydrophilic and hydrophobic surfaces. J Colloid Interface Sci. 2009; 331: 60-64. doi: 10.1016/j.jcis.2008.11.025 PMID: 19038397
6. Hassan M, Kjos M, Nes IF, Diep DB, Lotfipour F. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol. 2012; 113: 723-736. doi: 10.1111/j.1365-2672.2012.05338.x PMID: 22583565
7. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010; 23: 160-201. doi: 10.1128/CMR.00037-09 PMID: 20065329
8. Wenzel RP, Bearman G, Edmond MB. Screening for MRSA: a flawed hospital infection control intervention. Infect Control Hosp Epidemiol. 2008; 29: 1012-1018. doi: 10.1086/593120 PMID: 18937571
9. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med. 2006; 34: 653-659. PMID: 16505649
10. Witte W, Cuny C, Klare I, Nübel U, Strommenger B, Werner G. Emergence and spread of antibioticresistant Gram-positive bacterial pathogens. Int J Med Microbiol. 2008; 298: 365-377. doi: 10.1016/j. ijmm.2007.10.005 PMID: 18325835
11. Richards CL Jr. Preventing antimicrobial-resistant bacterial infections among older adults in long-term care facilities. J Am Med Dir Assoc. 2006; 7(3 Suppl): S89-S96, 88. PMID: 16500292
12. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents. 2000; 16 Suppl 1: S3-S10. PMID: 11137402
13. Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin?-Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010; 15: 507-513. PMID: 21163725
14. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013; 68: 4-11. doi: 10.1093/jac/dks354 PMID: 22949625
15. World Health Organization (WHO). International Classification of Diseases (ICD). Available: http:// www.who.int/classification/icd/en/. Accessed 6 June 2015.
16. Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy. 2005; 51: 227-233. PMID: 16103664
17. Niederman MS, Mandell LA, Anzeuto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163: 1730-1754. PMID: 11401897
18. Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician. 2011; 83: 1299-1306. PMID: 21661712
19. Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med. 1987; 8: 119-134. PMID: 3552385
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Wayne, Pa: Clinical and Laboratory Standards Institute; 2012.
21. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints 2011-2014. Available: http://www.eucast.org. Accessed 6 June 2015.
22. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966; 45: 493-496. PMID: 5325707
23. Lim WS, Smith DL, Wise MP, Welham SA. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. BMJ Open Respir Res. 2015; 2: e000091. doi: 10.1136/bmjresp-2015-000091 PMID: 26019876
24. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010; 23: 616-687. doi: 10.1128/CMR.00081-09 PMID: 20610826
25. Cardenas PA, Alarcón M, Narvaez I, Salazar R, Falconí G, Espinel M, et al. Staphylococcus aureus outbreak in the intensive care unit of the largest public hospital in Quito, Ecuador. Int Microbiol. 2013; 16: 81-86. PMID: 24400525
26. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008; 46 Suppl 5: S378-S385. doi: 10.1086/533594 PMID: 18462093
27. Almirall J, Cabré M, Clavé P. Complications of oropharyngeal dysphagia: aspiration pneumonia. Nestle Nutr Inst Workshop Ser. 2012; 72: 67-76. doi: 10.1159/000339989 PMID: 23052002
28. DeLegge MH. Aspiration pneumonia: incidence, mortality, and at-risk populations. JPEN J Parenter Enteral Nutr. 2002; 26(6 Suppl): S19-S24; discussion S24-S25. PMID: 12405619
29. Chaiwarith R, Pacharasupal P, Sirisanthana T. Epidemiology, clinical characteristics and treatment outcomes of healthcare-associated methicillin-resistant Staphylococcus aureus BLOODSTREAM infections at Chiang Mai University Hospital: a retrospective study. Southeast Asian J Trop Med Public Health. 2014; 45(4): 897-905.
30. Reith K. Der Kampf gegen gefährliche Keime im Krankenhaus. Westdeutsche Zeitung. 2015. [in German]. Available: http://www.wz-newsline.de/lokales/wuppertal/der-kampf-gegen-gefaehrliche-keimeim- krankenhaus-1.1836784. Accessed 29 August 2015.
31. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006; 42 Suppl 1: S5-S12. PMID: 16323120
32. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis. 2006; 42 Suppl 1: S25-S34. PMID: 16323116
33. Appelbaum PC, Bozdogan B. Vancomycin resistance in Staphylococcus aureus. Clin Lab Med. 2004; 24: 381-402. PMID: 15177846
34. Dombrádi Z, Dobay O, Nagy K, Kozák A, Dombrádi V, Szabó J. Prevalence of vanC vancomycin-resistant enterococci in the teaching hospitals of the University of Debrecen, Hungary. Microb Drug Resist. 2012; 18: 47-51. doi: 10.1089/mdr.2011.0014 PMID: 21649462
35. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007; 45 Suppl 3: S184-S190. PMID: 17712745
36. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001; 32: 402-412. Epub 2001 Jan 26. PMID: 11170948
37. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010; 38: 1802-1808. doi: 10.1097/CCM.0b013e3181eb3b96 PMID: 20639754
38. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011; 139: 1148-1155. doi: 10.1378/chest.10-1556 PMID: 20864609
39. Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015; 71: 107-115. doi: 10.1007/s00228-014-1775-x PMID: 25355172
40. Segarra-Newnham M, Church TJ. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Ann Pharmacother. 2012; 46: 1678-1687. doi: 10.1345/aph.1R370 PMID: 23232021
41. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open. 2013; 3: e003912. doi: 10.1136/ bmjopen-2013-003912 PMID: 24127058
42. Welte T, Pletz MW. Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents. 2010; 36: 391-400. doi:10. 1016/j.ijantimicag.2010.06.045 PMID: 20724119
43. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol. 2006; 71: 968-980. Epub 2006 Jan 18. PMID: 16412985
44. Johnson AP, Uttley AH, Woodford N, George RC. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev. 1990; 3: 280-291. PMID: 2143434
45. Martín-Loeches I, Diaz E, Vallés J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014; 20: 516-524. doi: 10.1097/MCC.0000000000000124 PMID: 25188366
46. Schmitz FJ, Krey A, Sadurski R, Verhoef J, Milatovic D, Fluit AC; European SENTRY Participants. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J Antimicrob Chemother. 2001; 47: 239-240. PMID: 11157916
47. Trzcinski K, Cooper BS, HryniewiczW, Dowson CG. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2000; 45: 763-770. PMID: 10837427
48. Jung YJ, Koh Y, Hong SB, Chung JW, Ho Choi S, Kim NJ, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010; 38: 175-180. PMID: 20050336
49. Jean SS, Hsueh PR. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother. 2011; 12: 2145-2148. doi: 10.1517/ 14656566.2011.599320 PMID: 21895553
50. Tremblay S, Lau TT, Ensom MH. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? Ann Pharmacother. 2013; 47: 1045-1054. doi:10. 1345/aph.1R726 PMID: 23715070
51. Tan CK, Lai CC, Lin SH, Hsueh PR. Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment. Crit Care Med. 2010; 38: 1754; author reply 1754-1755. doi: 10.1097/CCM. 0b013e3181db7d28 PMID: 20647809
52. Goldberg E, Paul M, Talker O, Samra Z, Raskin M, Hazzan R, et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother. 2010; 65: 1779-1783. doi: 10.1093/jac/dkq179 PMID: 20507860
53. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992; 117: 390-398. PMID: 1503330
54. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009; 18: 921-944. doi:10. 1517/13543780902967624 PMID: 19548851
55. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother. 2001; 48: 209-217. PMID: 11481290
56. Chen C, Chen Y, Wu P, Chen B. Update on new medicinal applications of gentamicin: evidence-based review. J Formos Med Assoc. 2014; 113: 72-82. doi: 10.1016/j.jfma.2013.10.002 PMID: 24216440
57. Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med. 2002; 28: 426-431. Epub 2002 Mar 6. PMID: 11967596
58. Lentino JR, Hennein H, Krause S, Pappas S, Fuller G, Schaaff D, et al. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies. Infect Control. 1985; 6: 267-272. PMID: 3847402
59. García C, Rijnders MI, Bruggeman C, Samalvides F, Stobberingh EE, Jacobs J. Antimicrobial resistance and molecular typing of Staphylococcus aureus bloodstream isolates from hospitals in Peru. J Infect. 2012; 65: 406-411. doi: 10.1016/j.jinf.2012.06.009 PMID: 22750236
60. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 1995; 39: 1764-1771. PMID: 7486916
61. Arsalan A, Naqvi SB, Ali SA, Ahmed S, Shakeel O. In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi. Pak J Pharm Sci. 2015; 28: 841-847. PMID: 26004702
62. Sörensen JH, Lilja M, Sörensen TC, Åstrand M, Procter P, Fuchs S, et al. Biomechanical and antibacterial properties of Tobramycin loaded hydroxyapatite coated fixation pins. J Biomed Mater Res B Appl Biomater. 2014; 102: 1381-1392. doi: 10.1002/jbm.b.33117 PMID: 24677812
63. Hernández-Porto M, Lecuona M, Aguirre-Jaime A, Castro B, Delgado T, Cuervo M, et al. Antimicrobial resistance and molecular analysis of methicillin-resistant Staphylococcus aureus collected in a Spanish hospital. Microb Drug Resist. 2015; 21: 201-208. doi: 10.1089/mdr.2014.0139 PMID: 25365597
64. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014; 11: 425-434. doi: 10.1513/AnnalsATS.201311-395FR PMID: 24673698
65. Skov R, Frimodt-Møller N, Espersen F. Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility testing using NCCLS methodology for fusidic acid. Diagn Microbiol Infect Dis. 2001; 40: 111-116. PMID: 11502378
66. Vitkauskiene A, Sakalauskas R, Dudzevicius V. [The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests]. Medicina (Kaunas). 2003; 39: 254-259. Lithuanian.
67. Chen HJ, Hung WC, Tseng SP, Tsai JC, Hsueh PR, Teng LJ. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2010; 54: 4985-4991. doi:10. 1128/AAC.00523-10 PMID: 20855746
68. Nakashio S, Nakamura M. In vitro activity of cefotaxime against clinically significant pathogens. Drugs. 1988; 35 Suppl 2: 14-21. PMID: 3260852
69. Masuyoshi S, Arai S, Miyamoto M, Mitsuhashi S. In vitro antimicrobial activity of cefotaxime, a new cephalosporin. Antimicrob Agents Chemother. 1980; 18: 1-8. PMID: 6251749
70. Jones RN, Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis. 1982; 4 Suppl: S300-S315. PMID: 6294779
71. Lemmen SW, Häfner H, Klik S, Lütticken R, Zolldann D. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy. 2003; 49: 33-35. PMID: 12714807
72. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int J Antimicrob Agents. 2009; 33: 52-57. doi:10. 1016/j.ijantimicag.2008.07.017 PMID: 18835763
73. Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009; 53: 3437-3441. doi:10. 1128/AAC.00317-09 PMID: 19487449
74. Lee S, Kwon KT, Kim HI, Chang HH, Lee JM, Choe PG, et al. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist. 2014; 20: 568-574. doi: 10.1089/mdr.2013.0229 PMID: 25000230
75. Oʇuz VA, Yapar N, Sezak N, Cavuş SA, Kurutepe S, Peksel H, et al. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci]. Mikrobiyol Bul. 2009; 43: 37-44. Turkish. PMID: 19334378
76. Rincón S, Reyes J, Carvajal LP, Rojas N, Cortés F, Panesso D, et al. Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals. J Antimicrob Chemother. 2013; 68: 2773-2778. doi: 10.1093/jac/dkt254 PMID: 23794599
77. Wang H, Liu YL, Chen MJ, Xu YC, Sun HL, Yang QW, et al. [Antimicrobial susceptibility of communityacquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. Zhonghua Jie He He Hu Xi Za Zhi. 2012; 35: 113-119. Chinese. PMID: 22455967
78. Bogdanov MB, Chernen'kaia TV. [Microbiological evaluation of differences between cephalosporins of second and third generations in general hospital]. Antibiot Khimioter. 2003; 48: 27-30. Russian.
79. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005; 40: 280-285. Epub 2004 Dec 21. PMID: 15655748
80. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002; 62: 13-59. PMID: 11790155
81. Peterson LR, Quick JN, Jensen B, Homann S, Johnson S, Tenquist J, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. Arch Intern Med. 1990; 150: 2151-2155. PMID: 2222100
82. Valour F, Chebib N, Gillet Y, Reix P, Laurent F, Chidiac C, et al. [Staphylococcus aureus broncho-pulmonary infections]. Rev Pneumol Clin. 2013; 69: 368-382. French. doi: 10.1016/j.pneumo.2013.08. 004 PMID: 24183294
83. Zervosen A, Sauvage E, Frère JM, Charlier P, Luxen A. Development of new drugs for an old target: the penicillin binding proteins. Molecules. 2012; 17: 12478-12505. doi: 10.3390/molecules171112478 PMID: 23095893
84. Contreras-Martel C, Amoroso A, Woon EC, Zervosen A, Inglis S, Martins A, et al. Structure-guided design of cell wall biosynthesis inhibitors that overcome β-lactam resistance in Staphylococcus aureus (MRSA). ACS Chem Biol. 2011; 6: 943-951. doi: 10.1021/cb2001846 PMID: 21732689
85. Wise R. A review of the mechanisms of action and resistance of antimicrobial agents. Can Respir J. 1999; 6 Suppl A: 20A-2A. PMID: 10202228
86. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010; 23: 160-201. doi: 10.1128/CMR.00037-09 PMID: 20065329
87. Ishii Y. [Antibiotic resistant genes]. Rinsho Byori. 2013; 61: 1136-1144. Japanese. PMID: 24605547